Jeevan Scientific Technology
70.05
+1.05(+1.52%)
Market Cap₹110.96 Cr
PE Ratio-52.67
IndustryHealthcare
Company Performance:
1D+1.52%
1M+4.55%
6M+65.56%
1Y+59.24%
5Y-0.28%
View Company Insightsright
More news about Jeevan Scientific Technology
08Nov 25
Jeevan Scientific Technology Completes US FDA Remote Evaluation Successfully
Jeevan Scientific Technology Limited successfully completed a Remote Interactive Evaluation (RIE) by the US FDA for its Clinical Pharmacology facility. The evaluation, conducted from October 17 to November 6, 2025, covered BA/BE studies, operations, systems, and procedures, concluding with no critical observations. This outcome demonstrates the company's adherence to regulatory standards and may enhance its credibility in the pharmaceutical research sector.
 no imag found
18Oct 25
Padmaja Private Trust Acquires 7.53% Stake in Jeevan Scientific Technology
Padmaja Private Trust has acquired a substantial 7.53% stake in Jeevan Scientific Technology Limited through preferential allotment of 15 lakh equity shares worth Rs 6 crore. The acquisition, completed on January 2, 2026, triggered SEBI disclosure requirements under Regulation 29(1) as the trust crossed the substantial acquisition threshold. This forms part of the company's successful Rs 30.74 crore capital raising initiative, which will fund expansion plans including API/formulation unit acquisitions and working capital requirements.
 no imag found
15Oct 25
Jeevan Scientific Technology Unveils Rs. 30.74 Crore Capital Raising Plan
Jeevan Scientific Technology Limited (JSTL) has approved a capital raising plan of Rs. 30.74 crore through convertible warrants and equity shares. The plan includes issuing 35,00,000 convertible warrants at Rs. 40 per warrant and 41,85,000 equity shares at Rs. 40 per share. The warrants will be allotted to both promoters and non-promoters, while the equity shares are exclusively for non-promoters. The company also plans to increase its authorized share capital from Rs. 21 crore to Rs. 25 crore. An Extraordinary General Meeting is scheduled for November 12, 2025, to seek shareholder approval. Post-allotment, promoters' holding is expected to be 38.37%, with public holding at 61.63%.
 no imag found
1 Year Returns:+59.24%
Industry Peers
Syngene International
435.05
(+0.16%)
Indegene
477.15
(+0.52%)
Suven Life Sciences
148.93
(-1.71%)
Vimta Labs
470.40
(+0.60%)
Take Solutions
46.68
(-4.44%)
Bilcare
65.03
(+1.10%)
Adeshwar Meditex
21.00
(-100.00%)
Vanta Bioscience
19.89
(-100.00%)